These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7706163)

  • 1. In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis.
    Pastor A; Pemán J; Cantón E
    J Antimicrob Chemother; 1994 Nov; 34(5):679-85. PubMed ID: 7706163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between the sensitivity of Pseudomonas aeruginosa and the post-antibiotic effect of sparfloxacin and ciprofloxacin].
    Pastor A; Cantón E; Pemán J
    Rev Esp Quimioter; 1998 Dec; 11(4):333-8. PubMed ID: 9990147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents.
    Louie A; Baltch AL; Ritz WJ; Smith RP
    J Antimicrob Chemother; 1991 Jun; 27(6):793-9. PubMed ID: 1657857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of sparfloxacin compared with those of five other quinolones.
    Cantón E; Pemán J; Jimenez MT; Ramón MS; Gobernado M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):558-65. PubMed ID: 1320362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postantibiotic effect, and postantibiotic effect of subinhibitory concentrations, of sparfloxacin on gram-negative bacteria.
    Odenholt-Tornqvist I; Bengtsson S
    Chemotherapy; 1994; 40(1):30-6. PubMed ID: 8306813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of quinolones resistance in Escherichia coli, Staphylococcus aureus and Pseudomonas areuginosa].
    Feng P; Yu R; Xia P; Lü X; Zhu S
    Hua Xi Yi Ke Da Xue Xue Bao; 2001 Dec; 32(4):501-4. PubMed ID: 12528531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.
    Cooper MA; Andrews JM; Ashby JP; Matthews RS; Wise R
    J Antimicrob Chemother; 1990 Nov; 26(5):667-76. PubMed ID: 2079449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
    Houston AK; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of subinhibitory concentrations of ciprofloxacin against Pseudomonas aeruginosa as determined by the killing curve method and the postantibiotic effect.
    Zhanel GG; Crampton J; Kim S; Nicolle LE; Davidson RJ; Hoban DJ
    Chemotherapy; 1992; 38(6):388-94. PubMed ID: 1288962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents.
    Gradelski E; Kolek B; Bonner DP; Valera L; Minassian B; Fung-Tomc J
    Int J Antimicrob Agents; 2001 Feb; 17(2):103-7. PubMed ID: 11165113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
    Odenholt I; Löwdin E; Cars O
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
    Majtán V; Hostacká A
    Folia Microbiol (Praha); 1996; 41(3):228-32. PubMed ID: 9449771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of lomefloxacin SC 47111 (NY-198) and ciprofloxacin against selected pathogens.
    Stratton CW; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):29S-34S. PubMed ID: 2791495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Chemotherapy; 1992; 38(2):99-106. PubMed ID: 1317282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.